Therapeutic Advances in Cardiovascular Disease (May 2024)

Inhibitory effect of microRNA-21 on pathways and mechanisms involved in cardiac fibrosis development

  • Amirreza Khalaji,
  • Saba Mehrtabar,
  • Armin Jabraeilipour,
  • Nadia Doustar,
  • Hamed Rahmani Youshanlouei,
  • Amir Tahavvori,
  • Payam Fattahi,
  • Seyed Mohammad Amin Alavi,
  • Seyed Reza Taha,
  • Andarz Fazlollahpour-Naghibi,
  • Mahdieh Shariat Zadeh

DOI
https://doi.org/10.1177/17539447241253134
Journal volume & issue
Vol. 18

Abstract

Read online

Cardiac fibrosis is a pivotal cardiovascular disease (CVD) process and represents a notable health concern worldwide. While the complex mechanisms underlying CVD have been widely investigated, recent research has highlighted microRNA-21’s (miR-21) role in cardiac fibrosis pathogenesis. In this narrative review, we explore the molecular interactions, focusing on the role of miR-21 in contributing to cardiac fibrosis. Various signaling pathways, such as the RAAS, TGF-β, IL-6, IL-1, ERK, PI3K-Akt, and PTEN pathways, besides dysregulation in fibroblast activity, matrix metalloproteinases (MMPs), and tissue inhibitors of MMPs cause cardiac fibrosis. Besides, miR-21 in growth factor secretion, apoptosis, and endothelial-to-mesenchymal transition play crucial roles. miR-21 capacity regulatory function presents promising insights for cardiac fibrosis. Moreover, this review discusses numerous approaches to control miR-21 expression, including antisense oligonucleotides, anti-miR-21 compounds, and Notch signaling modulation, all novel methods of cardiac fibrosis inhibition. In summary, this narrative review aims to assess the molecular mechanisms of cardiac fibrosis and its essential miR-21 function.